Patent classifications
C07D495/16
INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE
The present disclosure is directed to compounds of Formula (I) and methods of their use and preparation, as well as compositions comprising compounds of Formula (I).
##STR00001##
Carbazole derivatives
The present invention relates to carbazole derivatives, especially for use in electronic devices. The invention further relates to a process for preparing the compounds of the invention and to electronic devices comprising these.
SULFUROUS COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES
The present invention relates to sulfurous compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices containing said compounds.
SULFUROUS COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES
The present invention relates to sulfurous compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices containing said compounds.
Macrocyclic MCL-1 Inhibitors and Methods of Use
The present disclosure provides for compounds of formula (I)
##STR00001##
wherein A.sup.2, A.sup.3, A.sup.4, A.sup.6, A.sup.7, A.sup.8, A.sup.15, R.sup.A, R.sup.5, R.sup.9, R.sup.10A, R.sup.10B, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
Macrocyclic MCL-1 Inhibitors and Methods of Use
The present disclosure provides for compounds of formula (I)
##STR00001##
wherein A.sup.2, A.sup.3, A.sup.4, A.sup.6, A.sup.7, A.sup.8, A.sup.15, R.sup.A, R.sup.5, R.sup.9, R.sup.10A, R.sup.10B, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).
MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
- Wilfried Braje ,
- George Doherty ,
- Katja Jantos ,
- Cheng Ji ,
- Andrew Judd ,
- Aaron Kunzer ,
- Anthony Mastracchio ,
- Xiaohong Song ,
- Andrew Souers ,
- Gerard Sullivan ,
- Zhi-Fu Tao ,
- Chunqiu Lai ,
- Andreas Kling ,
- Frauke Pohlki ,
- Jesse Teske ,
- Michael Wendt ,
- Patrick Brady ,
- Xilu Wang ,
- Thomas Penning ,
- Yujia Dai ,
- Jane Gong ,
- Roberto Risi ,
- Yiyun Yu ,
- Guidong ZHU ,
- Dominique POTIN ,
- Fabrice Guillier
The present disclosure provides for compounds of Formula (I)
##STR00001##
wherein A.sup.2, A.sup.3, A.sup.4, A.sup.6, A.sup.7, A.sup.8, A.sup.15, R.sup.A, R.sup.5, R.sup.9, R.sup.10A, R.sup.10B, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
- Wilfried Braje ,
- George Doherty ,
- Katja Jantos ,
- Cheng Ji ,
- Andrew Judd ,
- Aaron Kunzer ,
- Anthony Mastracchio ,
- Xiaohong Song ,
- Andrew Souers ,
- Gerard Sullivan ,
- Zhi-Fu Tao ,
- Chunqiu Lai ,
- Andreas Kling ,
- Frauke Pohlki ,
- Jesse Teske ,
- Michael Wendt ,
- Patrick Brady ,
- Xilu Wang ,
- Thomas Penning ,
- Yujia Dai ,
- Jane Gong ,
- Roberto Risi ,
- Yiyun Yu ,
- Guidong ZHU ,
- Dominique POTIN ,
- Fabrice Guillier
The present disclosure provides for compounds of Formula (I)
##STR00001##
wherein A.sup.2, A.sup.3, A.sup.4, A.sup.6, A.sup.7, A.sup.8, A.sup.15, R.sup.A, R.sup.5, R.sup.9, R.sup.10A, R.sup.10B, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
The present disclosure provides for compounds of Formula (I)
##STR00001##
wherein A.sup.2, A.sup.3, A.sup.4, A.sup.6, A.sup.7, A.sup.8, A.sup.15, R.sup.A, R.sup.5, R.sup.9, R.sup.10A, R.sup.10B, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
The present disclosure provides for compounds of Formula (I)
##STR00001##
wherein A.sup.2, A.sup.3, A.sup.4, A.sup.6, A.sup.7, A.sup.8, A.sup.15, R.sup.A, R.sup.5, R.sup.9, R.sup.10A, R.sup.10B, R.sup.11, R.sup.12, R.sup.13, R.sup.14, R.sup.16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).